New Immunotherapy Trains Patients’ Bodies to Attack Cancer

By targeting tumors based on genetic makeup, a new precision immunotherapy teaches patients’ bodies to fight cancer.

While most FDA-approved cancer drugs are based on the disease type, pembrolizumab is focuses on genetics to attack tumors, allowing a patient’s immune system to “learn” how to effectively recognize and target the illness.

The drug provides doctors with another possible treatment for certain cancers, broadening treatment options beyond chemotherapy.